Lilly lawsuit could preserve $3.3bn of Sanofi revenues
This article was originally published in Scrip
The mere act of filing a lawsuit against Lilly appears to have boosted Sanofi's top-line prospects to the tune of several billion dollars. The firm, which has made a tactical play that should hold a biosimilar version of its top-selling product off the US market for an extra 16 months even if it eventually loses the patent battle, could make an extra $3.3bn in sales for the four years from 2015 to 2018, according to the revised forecast from Goldman Sachs.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.